12876_2022_2416_MOESM1_ESM.docx (37.77 kB)
Additional file 1 of Hepatitis C treatment outcomes for Australian First Nations Peoples: equivalent SVR rate but higher rates of loss to follow-up
journal contribution
posted on 2022-07-13, 05:38 authored by Paul J. Clark, Patricia C. Valery, James Ward, Simone I. Strasser, Martin Weltman, Alexander Thompson, Miriam T. Levy, Barbara Leggett, Amany Zekry, Julian Rong, Peter Angus, Jacob George, Steven Bollipo, Bruce McGarity, William Sievert, Gerry Macquillan, Edmund Tse, Amanda Nicoll, Amanda Wade, Geoff Chu, Damian Harding, Wendy Cheng, Geoff Farrell, Stuart K. RobertsAdditional file 1. Supplementary Table S1. List of Rx-Risk-V comorbidity categories with corresponding medicine groups and Anatomical Therapeutic Chemical (ATC), and ATC codes of medications dispensed to patients included in the Opera-C study. Supplementary Table 2. Prevalence of comorbidity categories included in the Rx-Risk-V according for First Nations Peoples and non-Indigenous Australians. Supplementary Table 3. Logistic regression analysis of factors associated with loss to follow-up among First Nations Peoples.
